The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
ApexOnco Front Page
Recent articles
ESMO and the Triple Meeting approach.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
Genmab acquires the Dutch biotech for $8bn.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
BNT329 enters the clinic, as do four other new ADCs.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
